

Media Release

Hyphens Pharma's TDF Fairence® T-Complex has efficacy tests affirmed in Journal of Cosmetic Dermatology

Singapore, 6 February 2020 – Hyphens Pharma Pte Ltd (“**Hyphens Pharma**”), a wholly-owned subsidiary company of Hyphens Pharma International Limited (“**凯帆药剂国际有限公司**”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that a skin penetration test of its TDF product, Fairence® T-Complex, a newly launched product in 2019, has been published in the internationally recognised Journal of Cosmetic Dermatology.

The published test result shows the efficacy of Fairence® T-Complex’s delivery system, which is able to significantly enhance skin penetration and deliver the ingredient into the skin by up to 11 times more than a competitor product. Fairence® T-Complex is scientifically designed with the Xcelarev® technology, a patented delivery system incorporating three key ingredients, namely Tranexamic acid, Niacinamide and Lactobionic acid to enhance skin lightening. The test results support further clinical studies as it hypothesised that a more robust and timely clinical response may be achieved especially in refractory patients.

Ms Ng Sue Phay, Associate Director, Product Development of Hyphens Pharma and lead author of the publication commented: “After years of research & development, we finally developed a breakthrough product. Through these published results, more dermatologists would recognise the positive effects of Fairence® T-Complex in the management of melasma.”

Tranexamic acid helps in the reduction of melanin production, improves overall skin tone, and concurrently reduces vascular factors that contribute to melasma. Niacinamide slows down the

transfer of melanin to the skin surface which reduces uneven pigmentation, and Lactobionic acid, a polyhydroxy acid with antioxidant properties increases cellular turnover, reduces the appearance of the dark spots.¹

Melasma is a common pigmentation disorder in which brown or gray patches appear on the skin, most commonly on face areas such as the bridge of the nose, forehead, cheeks and upper lips. Patients are usually people with darker skin, such as those of Latin/Hispanic, North African, African-American, Asian, Indian, Middle Eastern, or Mediterranean descent or have a blood relative who had melasma. Women are also much likely to get melasma as compared to men, who account for only about 10%² of people with melasma.

TDF is an established prescriptive skincare brand with strong reputation amongst medical professionals in many countries including Singapore, Malaysia, Indonesia and Hong Kong. TDF Derma Formula is the pioneer in alpha-hydroxy acids (AHA) glycolic acid formulations and a trusted brand in the field of dermatology. TDF skincare products provide science-based solutions with superior quality and proven efficacy across different skin types and skin conditions such as acne, hyperpigmentation, photoaging and aging skin.

End.

¹ <http://www.tdf-derma.com/products/hyperpigmentation/correct/?lang=en>

² <https://www.aad.org/public/diseases/a-z/melasma-causes>

About Hyphens Pharma International Limited

(www.hyphensgroup.com)

Hyphens Pharma International Limited and its subsidiaries (the "**Group**") is Singapore's leading specialty pharmaceutical and consumer healthcare group leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering six additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia, Oman and Bangladesh.

Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

Issued on behalf of the Company by Cogent Communications Pte Ltd.

For enquiries, please contact:

Ms Candy Soh, Tel: (65) 6704-9284, Mob: (65) 9816-8391

Email: candysoh@cogentcomms.com

Mr Gerald Woon, Tel: (65) 6704-9268, Mob: (65) 9694-8364

Email: woon@cogentcomms.com

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.